<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02316821</url>
  </required_header>
  <id_info>
    <org_study_id>RTA 402-005</org_study_id>
    <nct_id>NCT02316821</nct_id>
  </id_info>
  <brief_title>The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study</brief_title>
  <official_title>RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Chronic Kidney Disease and Type 2 Diabetes)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Hakko Kirin Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyowa Hakko Kirin Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of RTA 402 in chronic kidney
      disease (CKD) patients with type 2 diabetes in a double-blind, placebo-controlled study when
      this compound is administered once daily for 16 weeks in an intrapatient dose escalation
      design.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Number and types of adverse events</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Count of adverse events, by type, in the bardoxolone methyl arm compared to the placebo arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glomerular filtration rate (GFR) measured by inulin clearance after 16 weeks of study drug administration, compared to baseline GFR</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Change in GFR from baseline to 16 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in estimated GFR (eGFR) after 16 weeks of study drug administration, compared to baseline eGFR</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Change in eGFR from baseline to 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profiles of pharmacokinetics of plasma RTA 402 concentration: Trough (Pre-dose) and peak (2-4 hours post dose) concentrations of study drug at steady state</measure>
    <time_frame>Baseline, week 2, 6, 10, and 4 weeks after completion of study treatment</time_frame>
    <description>Relationship between the study drug dose and the trough (Pre-dose) and peak (2-4 hours post dose) concentrations of study drug at steady state</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">216</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>bardoxolone methyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bardoxolone methyl capsules, dosage To Be Determined, once daily for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules, once daily for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RTA 402</intervention_name>
    <arm_group_label>bardoxolone methyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CKD patients with type 2 diabetes mellitus

          -  Patients whose estimated GFR levels are eligible for this study

          -  Patients being treated with stable dose of angiotensin converting enzyme (ACE)
             inhibitors and/or angiotensin II receptor blocker (ARB) etc.

        Exclusion Criteria:

          -  Patients with type 1 diabetes mellitus

          -  Patients with known non-diabetic renal disease

          -  Patients with a history of renal transplantation

          -  Patients with mean systolic blood pressure &gt; 160 mmHg or diastolic blood pressure &gt; 90
             mmHg

          -  Patients with Hemoglobin A1c &gt; 10%

          -  Patients with cardiovascular disease specified in the study protocol etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2014</study_first_submitted>
  <study_first_submitted_qc>December 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2014</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Diabetic Nephropathies</keyword>
  <keyword>Kidney Diseases</keyword>
  <keyword>Renal Insufficiency, Chronic</keyword>
  <keyword>Diabetes Complications</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Glucose Metabolism Disorders</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Renal Insufficiency</keyword>
  <keyword>Urologic Diseases</keyword>
  <keyword>bardoxolone methyl</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

